{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:24:43Z","timestamp":1794003883828,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,11,2]],"date-time":"2027-11-02T00:00:00Z","timestamp":1825113600000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32"],"award-info":[{"award-number":["T32"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ijgc.2026.104976","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T23:31:05Z","timestamp":1786663865000},"page":"104976","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment strategies for oligometastatic and oligorecurrent epithelial ovarian cancer: a narrative review"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-0627","authenticated-orcid":false,"given":"David","family":"Viveros-Carre\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4240-2227","authenticated-orcid":false,"given":"Nathalia","family":"Mora-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Beshar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Agust\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Viveros-Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5799-2096","authenticated-orcid":false,"given":"Mar\u00eda","family":"Caicedo-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6375-9645","authenticated-orcid":false,"given":"Christina","family":"Fotopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Rauh-Hain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0093-0438","authenticated-orcid":false,"given":"Ren\u00e9","family":"Pareja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijgc.2026.104976_bib1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ygyno.2018.08.014","article-title":"Continuous improvement in primary debulking surgery for advanced ovarian cancer: do increased complete gross resection rates independently lead to increased progression-free and overall survival?","volume":"151","author":"Tseng","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104976_bib2","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.250116","article-title":"Imaging in advanced epithelial ovarian cancer: assessment of peritoneal spread","volume":"318","author":"Nougaret","year":"2026","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104976_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104976_bib4","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.ijgc.2026.104976_bib5","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med."},{"issue":"25","key":"10.1016\/j.ijgc.2026.104976_bib6","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.ijgc.2026.104976_bib7","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104976_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"20","key":"10.1016\/j.ijgc.2026.104976_bib9","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","article-title":"Secondary surgical cytoreduction for recurrent ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104976_bib10","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","article-title":"Randomized trial of cytoreductive surgery for relapsed ovarian cancer","volume":"385","author":"Harter","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104976_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(21)00006-1","article-title":"Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Shi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104976_bib12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.ijrobp.2024.09.036","article-title":"Stereotactic ablative radiation therapy for oligometastatic ovarian cancer lymph node disease: the MITO-RT3\/RAD Phase II trial","volume":"121","author":"Macchia","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104976_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/ijgc-2021-002709","article-title":"Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic\/persistent\/recurrent ovarian cancer: a prospective, multicenter phase II study (MITO-RT3\/RAD)","volume":"32","author":"Macchia","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104976_bib14","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1136\/ijgc-2022-003543","article-title":"Management of oligometastatic ovarian cancer recurrence during PARP inhibitor maintenance","volume":"32","author":"Palluzzi","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.104976_bib15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ygyno.2023.04.002","article-title":"PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients","volume":"173","author":"Gauduchon","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104976_bib16","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/ijgc-2024-005361","article-title":"Stereotactic radiotherapy for managing ovarian cancer oligoprogression under poly (ADP-ribose) polymerase inhibitors (PARPi)","volume":"34","author":"Durante","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104976_bib17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ijrobp.2024.09.010","article-title":"Stereotactic body radiation therapy for oligoprogressive ovarian cancer patients treated during poly(ADP-ribose)-polymerase inhibitor maintenance: efficacy and adverse events from the Epimetheo retrospective study","volume":"121","author":"Macchia","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"10.1016\/j.ijgc.2026.104976_bib18","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.ijrobp.2018.03.058","article-title":"Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday","volume":"101","author":"Lazzari","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104976_bib19","doi-asserted-by":"crossref","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","article-title":"A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): a collaboration of MITO, AIRO GYN, and MaNGO groups","volume":"25","author":"Macchia","year":"2020","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104976_bib20","doi-asserted-by":"crossref","first-page":"746","DOI":"10.2214\/AJR.05.1106","article-title":"Percutaneous radiofrequency ablation of ovarian cancer metastasis to the liver: indications, outcomes, and role in patient management","volume":"187","author":"Gervais","year":"2006","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104976_bib21","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1097\/IGC.0000000000000420","article-title":"Percutaneous cryoablation of ovarian cancer metastasis to the liver: initial experience in 13 patients","volume":"25","author":"Gao","year":"2015","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104976_bib22","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/IGC.0000000000000939","article-title":"Ultrasound-guided percutaneous radiofrequency ablation of liver metastasis from ovarian cancer: a single-center initial experience","volume":"27","author":"Liu","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.104976_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.793024","article-title":"Percutaneous radiofrequency ablation combined with chemotherapy versus chemotherapy only for ovarian cancer liver metastasis","volume":"11","author":"Wu","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104976_bib24","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/ijgc-2022-003444","article-title":"Radiofrequency and microwave ablation for treatment of recurrent gynecologic malignancies","volume":"32","author":"Zhang","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"8090","key":"10.1016\/j.ijgc.2026.104976_bib25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41586-025-09580-0","article-title":"Tracking clonal evolution during treatment in ovarian cancer using cell-free DNA","volume":"647","author":"Williams","year":"2025","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104976_bib26","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.annonc.2021.02.015","article-title":"The systemic treatment of recurrent ovarian cancer revisited","volume":"32","author":"Baert","year":"2021","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.ijgc.2026.104976_bib27","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104976_bib28","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/s41591-024-02981-0","article-title":"Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial","volume":"30","author":"Jiang","year":"2024","journal-title":"Nat Med"},{"issue":"10185","key":"10.1016\/j.ijgc.2026.104976_bib29","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.ijgc.2026.104976_bib30","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET Phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104976_bib31","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijrobp.2021.08.033","article-title":"Phase I trial of stereotactic MRI-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic ovarian cancer","volume":"112","author":"Henke","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"10.1016\/j.ijgc.2026.104976_bib32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijrobp.2025.03.032","article-title":"Treatment of oligometastatic parenchymal lesions in ovarian cancer with stereotactic ablative radiation therapy: a multicenter prospective Phase 2 trial (MITO RT3\/RAD)","volume":"123","author":"Macchia","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijgc.2026.104976_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1620922","article-title":"Stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (OMOC): a systematic review and meta-analysis of clinical outcomes and toxicity profiles","volume":"16","author":"Maiorano","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijgc.2026.104976_bib34","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ygyno.2024.07.006","article-title":"Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: an ad hoc subgroup analysis of PRIMA\/ENGOT-OV26\/GOG-3012","volume":"189","author":"Kamrava","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104976_bib35","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(24)00660-0","article-title":"Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial","volume":"26","author":"van der Lei","year":"2025","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104976_bib36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ygyno.2004.01.041","article-title":"Radiofrequency ablation of liver metastasis from ovarian adenocarcinoma: case report and literature review","volume":"93","author":"Bojalian","year":"2004","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104976_bib37","article-title":"SBRT in recurrent oligometastatic ovarian cancer: an EORTC Y-ECI GCG systematic review","volume":"53","author":"Huck","year":"2025","journal-title":"Clin Transl Radiat Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26005074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26005074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:32:07Z","timestamp":1794000727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26005074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1048891X26005074"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104976","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment strategies for oligometastatic and oligorecurrent epithelial ovarian cancer: a narrative review","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104976","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104976"}}